

# Tyler Jacks

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11823747/tyler-jacks-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241  
papers

80,326  
citations

115  
h-index

252  
g-index

252  
ext. papers

88,698  
ext. citations

23.8  
avg, IF

7.48  
L-index

#	Paper	IF	Citations
241	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells.. <i>Nature Communications</i> , <b>2022</b> , 13, 256	17.4	0
240	Lineage tracing reveals the phylogenetics, plasticity, and paths of tumor evolution.. <i>Cell</i> , <b>2022</b> ,	56.2	4
239	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues.. <i>Nature</i> , <b>2021</b> ,	50.4	6
238	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	20
237	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. <i>STAR Protocols</i> , <b>2021</b> , 2, 100583	1.4	0
236	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	7
235	Inducible de novo expression of neoantigens in tumor cells and mice. <i>Nature Biotechnology</i> , <b>2021</b> , 39, 64-73	44.5	12
234	Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	3
233	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. <i>Nature Communications</i> , <b>2021</b> , 12, 4995	17.4	5
232	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , <b>2021</b> , 39, 1342-1360.e14	24.3	18
231	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. <i>Nature Cancer</i> , <b>2021</b> , 2, 1071-1085	15.4	8
230	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. <i>Nature Communications</i> , <b>2021</b> , 12, 5680	17.4	7
229	Antigen dominance hierarchies shape TCF1 progenitor CD8 T cell phenotypes in tumors. <i>Cell</i> , <b>2021</b> , 184, 4996-5014.e26	56.2	13
228	SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	3
227	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1 CD8 T cells in tumor-draining lymph nodes. <i>Immunity</i> , <b>2021</b> , 54, 2338-2353.e6	32.3	17
226	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. <i>Nature Cancer</i> , <b>2020</b> , 1, 589-602	15.4	16
225	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	22

224	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. <i>ELife</i> , <b>2020</b> , 9,	8.9	26
223	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. <i>Cancer Research</i> , <b>2020</b> , 80, 3841-3854	10.1	13
222	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. <i>Cancer Cell</i> , <b>2020</b> , 38, 212-228.e13	24.3	57
221	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , <b>2020</b> , 38, 229-246.e13	14.3	76
220	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , <b>2020</b> , 181, 832-847.e18	56.2	34
219	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 513-521	11.5	27
218	Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 17460-17469	11.5	28
217	Commensal Microbiota Promote Lung Cancer Development via T Cells. <i>Cell</i> , <b>2019</b> , 176, 998-1013.e16	56.2	290
216	A dominant-negative effect drives selection of missense mutations in myeloid malignancies. <i>Science</i> , <b>2019</b> , 365, 599-604	33.3	127
215	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. <i>Nature</i> , <b>2019</b> , 571, 398-402	50.4	72
214	Identification of DHODH as a therapeutic target in small cell lung cancer. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	40
213	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. <i>Cell Reports</i> , <b>2019</b> , 29, 2998-3008.e8	10.6	24
212	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , <b>2019</b> , 574, 696-703	50.4	272
211	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. <i>Cancer Research</i> , <b>2018</b> , 78, 985-1002	10.1	21
210	Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. <i>Nature Protocols</i> , <b>2018</b> , 13, 217-234	18.8	41
209	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. <i>Nano Letters</i> , <b>2018</b> , 18, 2195-2208	11.5	16
208	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. <i>Cancer &amp; Metabolism</i> , <b>2018</b> , 6, 6	5.4	17
207	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. <i>Nature</i> , <b>2017</b> , 545, 355-359	50.4	190

206	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. <i>Nature Biotechnology</i> , <b>2017</b> , 35, 569-576	44.5	168
205	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. <i>Genes and Development</i> , <b>2017</b> , 31, 674-687	12.6	11
204	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. <i>Nature Medicine</i> , <b>2017</b> , 23, 1362-1368	50.5	301
203	Survival of pancreatic cancer cells lacking KRAS function. <i>Nature Communications</i> , <b>2017</b> , 8, 1090	17.4	88
202	Basic Mouse Methods for Clinician Researchers: Harnessing the Mouse for Biomedical Research <b>2017</b> , 291-312		0
201	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E5625-E5634	11.5	78
200	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. <i>Nature Communications</i> , <b>2016</b> , 7, 12685	17.4	35
199	A Modular Assembly Platform for Rapid Generation of DNA Constructs. <i>Scientific Reports</i> , <b>2016</b> , 6, 16836	4.9	34
198	PKM2, cancer metabolism, and the road ahead. <i>EMBO Reports</i> , <b>2016</b> , 17, 1721-1730	6.5	249
197	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. <i>Cancer Discovery</i> , <b>2016</b> , 6, 188-201	24.4	98
196	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. <i>Cell Metabolism</i> , <b>2016</b> , 23, 517-28	24.6	463
195	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. <i>Cell</i> , <b>2016</b> , 165, 896-909	56.2	147
194	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. <i>Genes and Development</i> , <b>2016</b> , 30, 1020-33	12.6	91
193	Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. <i>Science</i> , <b>2016</b> , 353, 1161-5	33.3	324
192	Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E6409-E6417	11.5	111
191	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. <i>Cell Metabolism</i> , <b>2016</b> , 24, 324-31	24.6	219
190	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. <i>Genome Biology</i> , <b>2015</b> , 16, 111	18.3	45
189	The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 553-64	8.9	71

188	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , <b>2015</b> , 21, 1163-71	50.5	275
187	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. <i>Immunity</i> , <b>2015</b> , 43, 579-90	32.3	242
186	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. <i>Genes and Development</i> , <b>2015</b> , 29, 1850-62	12.6	68
185	Genetic Mouse Models of Cancer <b>2015</b> , 145-154.e2		3
184	Applications of the CRISPR-Cas9 system in cancer biology. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 387-95	31.3	260
183	Recombinase-based conditional and reversible gene regulation via XTR alleles. <i>Nature Communications</i> , <b>2015</b> , 6, 8783	17.4	13
182	Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. <i>Cell</i> , <b>2014</b> , 156, 1298-1311	56.2	191
181	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. <i>Nature</i> , <b>2014</b> , 516, 428-31	50.4	278
180	Small RNA combination therapy for lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E3553-61	11.5	177
179	CRISPR-mediated direct mutation of cancer genes in the mouse liver. <i>Nature</i> , <b>2014</b> , 514, 380-4	50.4	521
178	Autophagy is required for glucose homeostasis and lung tumor maintenance. <i>Cancer Discovery</i> , <b>2014</b> , 4, 914-27	24.4	347
177	LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. <i>Molecular Cell</i> , <b>2014</b> , 54, 777-90	17.6	319
176	KRAS and YAP1 converge to regulate EMT and tumor survival. <i>Cell</i> , <b>2014</b> , 158, 171-84	56.2	482
175	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 551-3	44.5	694
174	A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. <i>Cell Reports</i> , <b>2013</b> , 5, 868-77	10.6	71
173	PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. <i>Cell</i> , <b>2013</b> , 155, 397-409	56.2	333
172	Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. <i>Molecular Cell</i> , <b>2013</b> , 50, 185-99	17.6	150
171	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 192-9	7.8	60

170	Integrated cisomic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. <i>Genes and Development</i> , <b>2013</b> , 27, 197-210	12.6	47
169	Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. <i>Genes and Development</i> , <b>2013</b> , 27, 1557-67	12.6	51
168	Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. <i>Cancer Discovery</i> , <b>2013</b> , 3, 993-1001	24.4	47
167	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. <i>Genes and Development</i> , <b>2013</b> , 27, 1447-61	12.6	433
166	Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. <i>Cancer Discovery</i> , <b>2013</b> , 3, 908-21	24.4	29
165	Characterizing deformability and surface friction of cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 7580-5	11.5	243
164	SnapShot: Lung cancer models. <i>Cell</i> , <b>2012</b> , 149, 246-246.e1	56.2	29
163	Expression of tumour-specific antigens underlies cancer immunoediting. <i>Nature</i> , <b>2012</b> , 482, 405-9	50.4	391
162	Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. <i>Cancer Cell</i> , <b>2012</b> , 21, 848-55	24.3	55
161	Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. <i>Molecular Cell</i> , <b>2011</b> , 43, 57-71	17.6	102
160	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 8773-8	11.5	181
159	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. <i>Blood</i> , <b>2011</b> , 117, 2022-32	2.2	110
158	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. <i>Blood</i> , <b>2011</b> , 118, 4666-73	2.2	76
157	Suppression of lung adenocarcinoma progression by Nkx2-1. <i>Nature</i> , <b>2011</b> , 473, 101-4	50.4	312
156	Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. <i>Cancer Cell</i> , <b>2011</b> , 19, 72-85	24.3	159
155	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , <b>2011</b> , 25, 1470-5	12.6	118
154	Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. <i>Molecular and Cellular Biology</i> , <b>2011</b> , 31, 1565-76	4.8	82
153	Response and resistance to NF-B inhibitors in mouse models of lung adenocarcinoma. <i>Cancer Discovery</i> , <b>2011</b> , 1, 236-47	24.4	104

152	Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. <i>Cancer Research</i> , <b>2011</b> , 71, 4040-7	10.1	67
151	Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. <i>Molecular Cancer Research</i> , <b>2011</b> , 9, 1339-45	6.6	20
150	Stage-specific sensitivity to p53 restoration during lung cancer progression. <i>Nature</i> , <b>2010</b> , 468, 572-5	50.4	208
149	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. <i>Nature Biotechnology</i> , <b>2010</b> , 28, 71-8	44.5	62
148	Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 10184-9	11.5	50
147	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. <i>Genes and Development</i> , <b>2010</b> , 24, 837-52	12.6	147
146	HIF-2alpha deletion promotes Kras-driven lung tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 14182-7	11.5	102
145	Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 20786-91	11.5	144
144	NF-kappaB fans the flames of lung carcinogenesis. <i>Cancer Prevention Research</i> , <b>2010</b> , 3, 403-5	3.2	19
143	A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. <i>Cell</i> , <b>2010</b> , 142, 409-19	56.2	1648
142	Imaging primary lung cancers in mice to study radiation biology. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 973-7	4	47
141	p63 and p73 transcriptionally regulate genes involved in DNA repair. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000680	6	107
140	Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. <i>Cancer Cell</i> , <b>2009</b> , 16, 379-89	24.3	257
139	Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. <i>Nature</i> , <b>2009</b> , 458, 223-7	50.4	3230
138	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. <i>Nature</i> , <b>2009</b> , 462, 108-12	50.4	1614
137	Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. <i>Nature</i> , <b>2009</b> , 462, 104-7	50.4	431
136	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. <i>Nature Protocols</i> , <b>2009</b> , 4, 1064-72	18.8	532
135	Dicer1 functions as a haploinsufficient tumor suppressor. <i>Genes and Development</i> , <b>2009</b> , 23, 2700-4	12.6	353

134	MicroRNAs and cancer: short RNAs go a long way. <i>Cell</i> , <b>2009</b> , 136, 586-91	56.2	762
133	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. <i>Cell</i> , <b>2009</b> , 137, 821-34	56.2	454
132	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. <i>Nature Genetics</i> , <b>2008</b> , 40, 600-8	36.3	441
131	Genetic Mouse Models of Cancer <b>2008</b> , 129-138		
130	A mouse plasma peptide atlas as a resource for disease proteomics. <i>Genome Biology</i> , <b>2008</b> , 9, R93	18.3	20
129	Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. <i>Cell</i> , <b>2008</b> , 132, 875-86	56.2	1332
128	Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. <i>Cell</i> , <b>2008</b> , 134, 62-73	56.2	336
127	Suppression of non-small cell lung tumor development by the let-7 microRNA family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3903-8	11.5	723
126	Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 9459-68	10.1	38
125	Requirement for Rac1 in a K-ras induced lung cancer in the mouse. <i>Cancer Research</i> , <b>2007</b> , 67, 8089-94	10.1	140
124	Impaired microRNA processing enhances cellular transformation and tumorigenesis. <i>Nature Genetics</i> , <b>2007</b> , 39, 673-7	36.3	1235
123	A spatially and temporally restricted mouse model of soft tissue sarcoma. <i>Nature Medicine</i> , <b>2007</b> , 13, 992-7	50.5	222
122	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. <i>EMBO Journal</i> , <b>2007</b> , 26, 784-94	13	64
121	Restoration of p53 function leads to tumour regression in vivo. <i>Nature</i> , <b>2007</b> , 445, 661-5	50.4	1388
120	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. <i>Genes and Development</i> , <b>2007</b> , 21, 694-707	12.6	101
119	Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- $\beta$ 1 haploinsufficiency. <i>Carcinogenesis</i> , <b>2007</b> , 28, 2589-96	4.6	11
118	Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. <i>Cancer Research</i> , <b>2007</b> , 67, 4648-56	10.1	38
117	Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. <i>Genes Chromosomes and Cancer</i> , <b>2006</b> , 45, 338-48	5	38



116	Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. <i>Cancer Research</i> , <b>2006</b> , 66, 242-7	10.1	116
115	Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 2527-31	10.1	64
114	The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 638-47	5.4	61
113	ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. <i>Cancer Research</i> , <b>2006</b> , 66, 7473-81	10.1	119
112	A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. <i>Nature Genetics</i> , <b>2006</b> , 38, 926-30	36.3	59
111	Identification of bronchioalveolar stem cells in normal lung and lung cancer. <i>Cell</i> , <b>2005</b> , 121, 823-35	56.2	1746
110	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. <i>Nature Genetics</i> , <b>2005</b> , 37, 48-55	36.3	361
109	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. <i>Nature Medicine</i> , <b>2005</b> , 11, 63-70	50.5	691
108	MicroRNA expression profiles classify human cancers. <i>Nature</i> , <b>2005</b> , 435, 834-8	50.4	7870
107	Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. <i>Cancer Cell</i> , <b>2005</b> , 7, 363-73	24.3	425
106	Mammalian RNAi: a practical guide. <i>BioTechniques</i> , <b>2005</b> , 39, 215-24	2.5	110
105	The differential effects of mutant p53 alleles on advanced murine lung cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 10280-8	10.1	401
104	Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. <i>Cancer Research</i> , <b>2005</b> , 65, 3610-6	10.1	28
103	Future of early detection of lung cancer: the role of mouse models. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4999s-5003s	12.9	17
102	Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. <i>Cancer Research</i> , <b>2005</b> , 65, 8166-73	10.1	52
101	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 14404-9	11.5	118
100	p53 Family Members: p63 and p73 <b>2005</b> , 187-198		
99	Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 8884-94	4.8	106

98	Susceptibility to astrocytoma in mice mutant for NF1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 13008-13	11.5	81
97	Cre-lox-regulated conditional RNA interference from transgenes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 10380-5	11.5	523
96	Cell type-specific effects of Rb deletion in the murine retina. <i>Genes and Development</i> , <b>2004</b> , 18, 1681-94	12.6	176
95	RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 25-34	20.1	76
94	Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. <i>EMBO Journal</i> , <b>2004</b> , 23, 3689-99	13	108
93	The Rb tumor suppressor is required for stress erythropoiesis. <i>EMBO Journal</i> , <b>2004</b> , 23, 4319-29	13	84
92	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. <i>Oncogene</i> , <b>2004</b> , 23, 973-80	9.2	93
91	Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. <i>Oncogene</i> , <b>2004</b> , 23, 4107-20	9.2	40
90	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. <i>Oncogene</i> , <b>2004</b> , 23, 7644-50	9.2	17
89	Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. <i>Cancer Cell</i> , <b>2004</b> , 5, 375-87	24.3	612
88	Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. <i>Cancer Research</i> , <b>2004</b> , 64, 2307-16	10.1	291
87	Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. <i>Cell</i> , <b>2004</b> , 119, 847-60	56.2	957
86	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 528-38	15.9	218
85	Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 9094-103	4.8	95
84	Targeted deletion reveals an essential function for the telomere length regulator Trf1. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 6533-41	4.8	137
83	Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. <i>Genes and Development</i> , <b>2003</b> , 17, 449-54	12.6	106
82	Neurofibromatosis type 1. <i>Methods in Molecular Biology</i> , <b>2003</b> , 222, 223-37	1.4	5
81	Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 644-8	1.2	20

80	Rb and N-ras function together to control differentiation in the mouse. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 5256-68	4.8	46
79	A big step in the study of small cell lung cancer. <i>Cancer Cell</i> , <b>2003</b> , 4, 163-6	24.3	50
78	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , <b>2003</b> , 4, 437-50	24.3	1772
77	Perp is a mediator of p53-dependent apoptosis in diverse cell types. <i>Current Biology</i> , <b>2003</b> , 13, 1985-90	6.3	91
76	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. <i>Nature</i> , <b>2003</b> , 424, 223-8	50.4	461
75	Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. <i>Molecular Cell</i> , <b>2003</b> , 12, 841-9	17.6	199
74	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. <i>Cancer Cell</i> , <b>2002</b> , 1, 408-10	24.3	28
73	ARF is not required for apoptosis in Rb mutant mouse embryos. <i>Current Biology</i> , <b>2002</b> , 12, 159-63	6.3	66
72	Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. <i>Oncogene</i> , <b>2002</b> , 21, 5990-7	9.2	36
71	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. <i>Nature</i> , <b>2002</b> , 415, 526-30	50.4	447
70	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. <i>Nature</i> , <b>2002</b> , 416, 560-4	50.4	718
69	Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 10394-9	5.4	182
68	Tumor suppression by a severely truncated species of retinoblastoma protein. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 3103-10	4.8	25
67	ARF mutation accelerates pituitary tumor development in Rb+/- mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16865-70	11.5	35
66	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 2948-53	11.5	157
65	Cancer modeling in the modern era: progress and challenges. <i>Cell</i> , <b>2002</b> , 108, 135-44	56.2	304
64	An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. <i>Cell</i> , <b>2002</b> , 109, 169-80	56.2	80
63	Taking the study of cancer cell survival to a new dimension. <i>Cell</i> , <b>2002</b> , 111, 923-5	56.2	253

62	Technologically advanced cancer modeling in mice. <i>Current Opinion in Genetics and Development</i> , <b>2002</b> , 12, 105-10	4.9	66
61	Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. <i>Molecular Immunology</i> , <b>2002</b> , 38, 701-8	4.3	13
60	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. <i>Seminars in Cancer Biology</i> , <b>2001</b> , 11, 177-91	12.7	24
59	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. <i>Oncogene</i> , <b>2001</b> , 20, 5054-8	9.2	569
58	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. <i>Nature</i> , <b>2001</b> , 410, 1111-5	6.4	932
57	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. <i>Genes and Development</i> , <b>2001</b> , 15, 3243-8	12.6	1376
56	The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. <i>Developmental Cell</i> , <b>2001</b> , 1, 63-72	10.2	288
55	NF1 tumor suppressor gene function: narrowing the GAP. <i>Cell</i> , <b>2001</b> , 104, 593-604	56.2	493
54	NF1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. <i>Nature Genetics</i> , <b>2000</b> , 26, 109-13	36.3	325
53	Role for the p53 homologue p73 in E2F-1-induced apoptosis. <i>Nature</i> , <b>2000</b> , 407, 645-8	50.4	546
52	Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. <i>Genes and Development</i> , <b>2000</b> , 14, 3037-50	12.6	487
51	NF1 and Gmcsf interact in myeloid leukemogenesis. <i>Molecular Cell</i> , <b>2000</b> , 5, 189-95	17.6	122
50	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. <i>Genes and Development</i> , <b>2000</b> , 14, 704-718	12.6	165
49	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on NF1-Deficient Hematopoietic Cells. <i>Blood</i> , <b>1999</b> , 94, 2469-2476	2.2	74
48	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. <i>Blood</i> , <b>1999</b> , 93, 3617-3623	2.2	46
47	Modeling human lung cancer in mice: similarities and shortcomings. <i>Oncogene</i> , <b>1999</b> , 18, 5318-24	9.2	110
46	The retinoblastoma gene family in differentiation and development. <i>Oncogene</i> , <b>1999</b> , 18, 7873-82	9.2	344
45	Insights into cancer from transgenic mouse models. <i>Journal of Pathology</i> , <b>1999</b> , 187, 43-60	9.4	93

44	Mouse models of tumor development in neurofibromatosis type 1. <i>Science</i> , <b>1999</b> , 286, 2172-6	33.3	387
43	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. <i>Blood</i> , <b>1999</b> , 93, 3617-3623	2.2	6
42	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. <i>Nature Genetics</i> , <b>1998</b> , 18, 360-4	36.3	248
41	Tumor suppressor mutations in mice: the next generation. <i>Current Opinion in Genetics and Development</i> , <b>1998</b> , 8, 304-10	4.9	14
40	Mutation of E2F-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. <i>Molecular Cell</i> , <b>1998</b> , 2, 293-304	17.6	339
39	p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. <i>Journal of Cell Biology</i> , <b>1998</b> , 141, 503-14	7.3	128
38	Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 7757-64	5.4	99
37	Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 187, 1893-902	16.6	131
36	RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. <i>Molecular Biology of the Cell</i> , <b>1998</b> , 9, 403-19	3.5	163
35	p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 206-20	4.8	72
34	Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm <sup>-/-</sup> mice. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 4385-90	4.8	90
33	Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 1055-64	4.8	439
32	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. <i>Nature Genetics</i> , <b>1997</b> , 15, 281-4	36.3	278
31	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. <i>Nature Genetics</i> , <b>1997</b> , 16, 336-7	36.3	15
30	Tumor suppressor gene mutations in mice. <i>Annual Review of Genetics</i> , <b>1996</b> , 30, 603-36	14.5	93
29	Tumor induction and tissue atrophy in mice lacking E2F-1. <i>Cell</i> , <b>1996</b> , 85, 537-48	56.2	620
28	Mechanisms of carcinogenesis and the mutant mouse. <i>Current Opinion in Genetics and Development</i> , <b>1996</b> , 6, 65-70	4.9	23
27	Lessons from the p53 mutant mouse. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1996</b> , 122, 319-27	4.9	29

26	Nf1 gene targeting: toward models and mechanisms. <i>Seminars in Cancer Biology</i> , <b>1996</b> , 7, 291-8	12.7	7
25	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. <i>Nature Genetics</i> , <b>1996</b> , 12, 144-8	36.3	474
24	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. <i>Nature</i> , <b>1996</b> , 379, 88-91	50.4	2026
23	A subset of p53-deficient embryos exhibit exencephaly. <i>Nature Genetics</i> , <b>1995</b> , 10, 175-80	36.3	501
22	Radiation-induced cell cycle arrest compromised by p21 deficiency. <i>Nature</i> , <b>1995</b> , 377, 552-7	50.4	1119
21	Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. <i>Nature</i> , <b>1995</b> , 377, 695-701	50.4	323
20	Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene NF1. <i>Endocrine Pathology</i> , <b>1995</b> , 6, 323-335	4.2	36
19	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. <i>Nature Genetics</i> , <b>1994</b> , 7, 353-61	36.3	664
18	Cooperative tumorigenic effects of germline mutations in Rb and p53. <i>Nature Genetics</i> , <b>1994</b> , 7, 480-4	36.3	348
17	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. <i>Nature</i> , <b>1994</b> , 371, 72-4	50.4	587
16	Sunburn and p53 in the onset of skin cancer. <i>Nature</i> , <b>1994</b> , 372, 773-6	50.4	1520
15	Tumor spectrum analysis in p53-mutant mice. <i>Current Biology</i> , <b>1994</b> , 4, 1-7	6.3	1731
14	p53-dependent apoptosis suppresses tumor growth and progression in vivo. <i>Cell</i> , <b>1994</b> , 78, 703-11	56.2	801
13	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. <i>Cell</i> , <b>1993</b> , 74, 957-67	56.2	2622
12	p53 is required for radiation-induced apoptosis in mouse thymocytes. <i>Nature</i> , <b>1993</b> , 362, 847-9	50.4	2565
11	Generation of normal lymphocyte populations by Rb-deficient embryonic stem cells. <i>Current Biology</i> , <b>1993</b> , 3, 405-13	6.3	34
10	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. <i>Cell</i> , <b>1992</b> , 70, 923-35	56.2	1242
9	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. <i>Cell</i> , <b>1992</b> , 71, 587-97	56.2	2767

8	Effects of an Rb mutation in the mouse. <i>Nature</i> , <b>1992</b> , 359, 295-300	50.4	1599
7	Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. <i>Nature</i> , <b>1988</b> , 331, 280-3	50.4	775
6	Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. <i>Cell</i> , <b>1988</b> , 55, 447-58	56.2	546
5	Roles of microRNAs in cancer and development322-337		
4	Spatially-Resolved Live Cell Tagging and Isolation Using Protected Photoactivatable Cell Dyes		1
3	The mutational landscape of EGFR-, MYC-, and Kras- driven genetically-engineered mouse models of lung adenocarcinoma		1
2	Longitudinal single cell profiling of regulatory T cells identifies IL-33 as a driver of tumor immunosuppression		1
1	Deciphering the immunopeptidome in vivo reveals new tumour antigens. <i>Nature</i> ,	50.4	3